| Name | Title | Contact Details |
|---|
MaxCyte is a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines.
BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.
Inimmue is a new biotechnology company founded by pharmaceutical industry veterans focused on developing next generation immunotherapeutics.
Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in patient care. vRad’s more than 400 radiologists serve 2,000+ facilities, reading 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment.
Just. is an integrated design company focused on the technology of biotherapeutics, from molecule to manufacturing plant. We believe that technological innovation will accelerate biotherapeutic development and dramatically reduce the cost of these vital medicines.